Symbols / BEAM Stock $27.11 +2.96% Beam Therapeutics Inc.

Healthcare • Biotechnology • United States • NMS
BEAM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. John M. Evans M.B.A.
Exch · Country NMS · United States
Market Cap 2.79B
Enterprise Value 1.74B
Income -65.98M
Sales 164.01M
FCF (ttm) -233.56M
Book/sh 11.71
Cash/sh 12.17
Employees 522
Insider 10d —
IPO Feb 06, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.63
PEG —
P/S 17.01
P/B 2.31
P/C —
EV/EBITDA -4.97
EV/Sales 10.59
Quick Ratio 16.25
Current Ratio 16.99
Debt/Eq 21.54
LT Debt/Eq —
EPS (ttm) -0.49
EPS next Y -4.82
EPS Growth —
Revenue Growth 3.25%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-07
ROA -15.76%
ROE -5.77%
ROIC —
Gross Margin -146.90%
Oper. Margin -3.38%
Profit Margin -40.23%
Shs Outstand 102.88M
Shs Float 87.97M
Insider Own 1.36%
Instit Own 106.98%
Short Float 31.53%
Short Ratio 9.71
Short Interest 20.94M
52W High 36.44
vs 52W High -25.60%
52W Low 15.35
vs 52W Low 76.61%
Beta 2.26
Impl. Vol. 0.39%
Rel Volume 0.96
Avg Volume 2.15M
Volume 2.05M
Target (mean) $51.07
Tgt Median $47.00
Tgt Low $26.00
Tgt High $80.00
# Analysts 15
Recom Strong_buy
Prev Close $26.33
Price $27.11
Change 2.96%
About

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$51.07
Mean price target
2. Current target
$27.11
Latest analyst target
3. DCF / Fair value
$-40.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.11
Low
$26.00
High
$80.00
Mean
$51.07

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-13 main Bernstein Outperform → Outperform $39
2026-03-26 main Citigroup Buy → Buy $68
2026-02-25 main RBC Capital Sector Perform → Sector Perform $26
2026-02-25 main Wedbush Outperform → Outperform $65
2026-02-20 init Canaccord Genuity — → Buy $74
2026-01-21 main Bernstein Outperform → Outperform $41
2026-01-07 init UBS — → Neutral $28
2025-11-24 init Evercore ISI Group — → Outperform $35
2025-10-10 reit HC Wainwright & Co. Buy → Buy $80
2025-10-09 main JP Morgan Overweight → Overweight $46
2025-09-15 reit HC Wainwright & Co. Buy → Buy $80
2025-08-06 main Barclays Equal-Weight → Equal-Weight $21
2025-05-07 main Guggenheim Buy → Buy $55
2025-05-07 main Wells Fargo Overweight → Overweight $70
2025-05-07 main Barclays Equal-Weight → Equal-Weight $25
2025-04-07 reit HC Wainwright & Co. Buy → Buy $80
2025-03-28 up B of A Securities Neutral → Buy $42
2025-03-12 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-10 up Scotiabank Sector Perform → Sector Outperform $40
2025-03-10 up Jones Trading Hold → Buy $34
News
RSS: Latest BEAM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 CIARAMELLA GIUSEPPE President — 11,810 $24.58 $290,290
2026-04-01 EVANS JOHN M. Chief Executive Officer — 30,078 $24.58 $739,317
2026-04-01 BELLON CHRISTINE Officer — 5,956 $24.58 $146,398
2026-04-01 SIMON AMY Officer — 6,700 $24.58 $164,686
2026-04-01 CAVANAGH BETHANY J Officer and Treasurer — 3,242 $24.58 $79,688
2026-03-31 EVANS JOHN M. Chief Executive Officer — 50,000 $22.37 $1,128,315
2026-03-31 EVANS JOHN M. Chief Executive Officer — 50,000 $0.67 $33,500
2026-03-31 CIARAMELLA GIUSEPPE President — 40,000 $0.00 $0
2026-03-31 EVANS JOHN M. Chief Executive Officer — 90,000 $0.00 $0
2026-03-31 EMANY SRAVAN KUMAR Chief Financial Officer — 31,750 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
139.74
+120.01%
63.52
-83.18%
377.71
+520.01%
60.92
Operating Revenue
139.74
+120.01%
63.52
-83.18%
377.71
+520.01%
60.92
Operating Expense
523.44
+9.26%
479.09
-13.55%
554.19
+38.76%
399.40
Research And Development
409.62
+11.44%
367.56
-15.96%
437.38
+40.37%
311.59
Selling General And Administration
113.82
+2.06%
111.53
-4.53%
116.81
+33.04%
87.81
General And Administrative Expense
113.82
+2.06%
111.53
-4.53%
116.81
+33.04%
87.81
Other Gand A
113.82
+2.06%
111.53
-4.53%
116.81
+33.04%
87.81
Total Expenses
523.44
+9.26%
479.09
-13.55%
554.19
+38.76%
399.40
Operating Income
-383.69
+7.67%
-415.57
-135.47%
-176.49
+47.86%
-338.48
Total Operating Income As Reported
-383.69
+7.67%
-415.57
-135.47%
-176.49
+47.86%
-338.48
EBITDA
-361.40
+8.19%
-393.64
-151.57%
-156.47
+50.47%
-315.90
Normalized EBITDA
-366.22
+4.48%
-383.41
-147.17%
-155.12
+59.06%
-378.91
Reconciled Depreciation
22.29
+1.68%
21.93
+9.56%
20.01
-11.36%
22.58
EBIT
-383.69
+7.67%
-415.57
-135.47%
-176.49
+47.86%
-338.48
Total Unusual Items
4.82
+147.14%
-10.23
-656.58%
-1.35
-102.15%
63.00
Total Unusual Items Excluding Goodwill
4.82
+147.14%
-10.23
-656.58%
-1.35
-102.15%
63.00
Special Income Charges
0.18
-88.69%
1.59
-83.66%
9.74
-48.48%
18.90
Restructuring And Mergern Acquisition
-0.18
+88.69%
-1.59
+83.66%
-9.74
+48.48%
-18.90
Net Income
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Pretax Income
-79.99
+78.77%
-376.70
-187.21%
-131.16
+49.59%
-260.18
Net Non Operating Interest Income Expense
43.73
-10.92%
49.09
+5.18%
46.68
+205.13%
15.30
Net Interest Income
43.73
-10.92%
49.09
+5.18%
46.68
+205.13%
15.30
Other Income Expense
259.97
+2641.48%
-10.23
-656.58%
-1.35
-102.15%
63.00
Gain On Sale Of Security
4.64
+139.27%
-11.82
-6.57%
-11.09
-125.15%
44.10
Tax Provision
0.00
-100.00%
0.04
-97.14%
1.37
-59.94%
3.41
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.28
-102.15%
13.23
Net Income Including Noncontrolling Interests
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Net Income From Continuing Operation Net Minority Interest
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Net Income From Continuing And Discontinued Operation
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Net Income Continuous Operations
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Normalized Income
-84.81
+76.86%
-366.51
-178.80%
-131.46
+61.21%
-338.86
Net Income Common Stockholders
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Diluted EPS
-0.81
+82.31%
-4.58
-166.28%
-1.72
+58.35%
-4.13
Basic EPS
-0.81
+82.31%
-4.58
-166.28%
-1.72
+58.35%
-4.13
Basic Average Shares
98.91
+20.16%
82.31
+6.69%
77.15
+10.19%
70.02
Diluted Average Shares
98.91
+20.16%
82.31
+6.69%
77.15
+10.19%
70.02
Diluted NI Availto Com Stockholders
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Earnings From Equity Interest
255.15
0.00
0.00
—
Earnings From Equity Interest Net Of Tax
—
0.00
0.00
+100.00%
-25.50
Total Other Finance Cost
-43.73
+10.92%
-49.09
-5.18%
-46.68
-205.13%
-15.30
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,481.18
+34.19%
1,103.82
-24.38%
1,459.71
+8.79%
1,341.71
Current Assets
1,268.69
+44.47%
878.15
-27.49%
1,211.04
+10.81%
1,092.90
Cash Cash Equivalents And Short Term Investments
1,245.21
+46.37%
850.74
-28.50%
1,189.88
+10.36%
1,078.13
Cash And Cash Equivalents
294.94
+4.60%
281.97
-35.31%
435.89
+87.27%
232.77
Other Short Term Investments
950.27
+67.07%
568.77
-24.56%
753.98
-10.81%
845.37
Receivables
—
—
—
0.00
Accounts Receivable
—
—
—
0.00
Prepaid Assets
—
—
—
—
Other Current Assets
23.48
-14.34%
27.41
+29.49%
21.17
+43.39%
14.76
Total Non Current Assets
212.49
-5.84%
225.68
-9.25%
248.67
-0.06%
248.82
Net PPE
205.18
-5.13%
216.28
-9.05%
237.81
+1.57%
234.13
Gross PPE
299.31
+3.79%
288.38
+0.14%
287.99
+8.96%
264.30
Accumulated Depreciation
-94.13
-30.54%
-72.11
-43.69%
-50.18
-66.33%
-30.17
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
8.01
+0.00%
8.01
+0.09%
8.00
+8.02%
7.41
Construction In Progress
2.82
+11.58%
2.53
-52.11%
5.28
+1.64%
5.20
Other Properties
177.72
+0.60%
176.65
+1.22%
174.52
+5.20%
165.90
Leases
110.76
+9.45%
101.19
+1.01%
100.19
+16.76%
85.80
Other Non Current Assets
7.31
-22.22%
9.40
-13.50%
10.87
-26.01%
14.69
Total Liabilities Net Minority Interest
242.82
-34.42%
370.28
-22.60%
478.38
-21.35%
608.24
Current Liabilities
96.94
-46.76%
182.07
-11.43%
205.56
-8.06%
223.59
Payables And Accrued Expenses
34.17
+55.63%
21.96
-65.07%
62.87
+128.13%
27.56
Payables
10.23
+164.30%
3.87
+139.39%
1.62
-82.09%
9.03
Accounts Payable
10.23
+164.30%
3.87
+139.39%
1.62
-82.09%
9.03
Current Accrued Expenses
23.94
+32.37%
18.09
-70.47%
61.25
+230.58%
18.53
Pensionand Other Post Retirement Benefit Plans Current
29.34
+36.02%
21.57
-0.93%
21.77
+13.87%
19.12
Current Debt And Capital Lease Obligation
14.36
+6.64%
13.47
+5.41%
12.78
+23.10%
10.38
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
14.36
+6.64%
13.47
+5.41%
12.78
+23.10%
10.38
Current Deferred Liabilities
6.66
-93.88%
108.86
+58.44%
68.71
-49.47%
135.97
Current Deferred Revenue
6.66
-93.88%
108.86
+58.44%
68.71
-49.47%
135.97
Other Current Liabilities
12.40
-23.51%
16.21
-58.90%
39.44
+29.05%
30.56
Total Non Current Liabilities Net Minority Interest
145.88
-22.49%
188.21
-31.01%
272.82
-29.07%
384.64
Long Term Debt And Capital Lease Obligation
139.76
-5.54%
147.96
-7.48%
159.91
-5.17%
168.62
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
139.76
-5.54%
147.96
-7.48%
159.91
-5.17%
168.62
Non Current Deferred Liabilities
0.00
-100.00%
33.22
-69.77%
109.89
-45.65%
202.18
Non Current Deferred Revenue
0.00
-100.00%
33.22
-69.77%
109.89
-45.65%
202.18
Other Non Current Liabilities
6.12
+274.62%
1.64
-45.88%
3.02
-78.17%
13.84
Stockholders Equity
1,238.36
+68.82%
733.54
-25.25%
981.33
+33.79%
733.47
Common Stock Equity
1,238.36
+68.82%
733.54
-25.25%
981.33
+33.79%
733.47
Capital Stock
1.02
+21.65%
0.84
+2.45%
0.82
+14.61%
0.71
Common Stock
1.02
+21.65%
0.84
+2.45%
0.82
+14.61%
0.71
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
101.75
+21.66%
83.63
+2.45%
81.63
+14.53%
71.28
Ordinary Shares Number
101.75
+21.66%
83.63
+2.45%
81.63
+14.53%
71.28
Additional Paid In Capital
2,877.45
+25.18%
2,298.66
+5.94%
2,169.80
+21.05%
1,792.55
Retained Earnings
-1,641.22
-4.76%
-1,566.63
-31.66%
-1,189.89
-12.53%
-1,057.36
Gains Losses Not Affecting Retained Earnings
1.11
+63.62%
0.68
+12.42%
0.60
+124.86%
-2.43
Other Equity Adjustments
1.11
+63.62%
0.68
+12.42%
0.60
+124.86%
-2.43
Total Equity Gross Minority Interest
1,238.36
+68.82%
733.54
-25.25%
981.33
+33.79%
733.47
Total Capitalization
1,238.36
+68.82%
733.54
-25.25%
981.33
+33.79%
733.47
Working Capital
1,171.75
+68.34%
696.08
-30.77%
1,005.48
+15.67%
869.30
Invested Capital
1,238.36
+68.82%
733.54
-25.25%
981.33
+33.79%
733.47
Total Debt
154.12
-4.52%
161.43
-6.52%
172.69
-3.53%
179.00
Capital Lease Obligations
154.12
-4.52%
161.43
-6.52%
172.69
-3.53%
179.00
Net Tangible Assets
1,238.36
+68.82%
733.54
-25.25%
981.33
+33.79%
733.47
Tangible Book Value
1,238.36
+68.82%
733.54
-25.25%
981.33
+33.79%
733.47
Derivative Product Liabilities
0.00
-100.00%
5.40
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-345.10
+0.62%
-347.25
-132.75%
-149.19
-762.29%
22.53
Cash Flow From Continuing Operating Activities
-345.10
+0.62%
-347.25
-132.75%
-149.19
-762.29%
22.53
Net Income From Continuing Operations
-79.99
+78.77%
-376.74
-184.28%
-132.53
+54.16%
-289.09
Depreciation Amortization Depletion
22.29
+1.68%
21.93
+9.56%
20.01
-11.36%
22.58
Depreciation
22.29
+1.68%
21.93
+9.56%
20.01
-11.36%
22.58
Depreciation And Amortization
22.29
+1.68%
21.93
+9.56%
20.01
-11.36%
22.58
Other Non Cash Items
24.71
+206.03%
8.08
+3754.30%
-0.22
+98.83%
-18.90
Stock Based Compensation
94.24
-21.89%
120.66
+22.32%
98.65
+16.99%
84.32
Operating Gains Losses
-255.45
-11143.27%
-2.27
+69.71%
-7.50
-568.75%
1.60
Gain Loss On Investment Securities
-0.30
+86.75%
-2.27
+69.71%
-7.50
+68.62%
-23.90
Unrealized Gain Loss On Investment Securities
-3.94
-127.97%
14.09
-24.20%
18.59
+192.04%
-20.20
Change In Working Capital
-131.02
-18.86%
-110.22
+5.35%
-116.45
-146.28%
251.63
Change In Receivables
—
0.00
+100.00%
-0.15
-100.05%
300.00
Change In Prepaid Assets
4.51
+184.33%
-5.35
+19.19%
-6.62
+14.63%
-7.75
Change In Payables And Accrued Expense
13.72
+124.56%
-55.88
-193.00%
60.09
+512.67%
-14.56
Change In Accrued Expense
7.68
+113.32%
-57.69
-185.25%
67.66
+499.59%
-16.93
Change In Payable
6.04
+234.26%
1.81
+123.85%
-7.58
-419.34%
2.37
Change In Account Payable
6.04
+234.26%
1.81
+123.85%
-7.58
-419.34%
2.37
Change In Other Working Capital
-135.42
-270.82%
-36.52
+77.11%
-159.56
-344.21%
-35.92
Change In Other Current Assets
—
—
0.00
0.00
Change In Other Current Liabilities
-13.84
-10.88%
-12.48
-20.42%
-10.36
-205.08%
9.86
Investing Cash Flow
-121.44
-165.64%
185.01
+157.53%
71.84
+115.57%
-461.34
Cash Flow From Continuing Investing Activities
-121.44
-165.64%
185.01
+157.53%
71.84
+115.57%
-461.34
Net PPE Purchase And Sale
-14.95
-67.07%
-8.95
+73.48%
-33.73
+31.09%
-48.95
Purchase Of PPE
-14.95
-67.07%
-8.95
+73.48%
-33.73
+31.09%
-48.95
Capital Expenditure
-14.95
-67.07%
-8.95
+73.48%
-33.73
+31.09%
-48.95
Net Investment Purchase And Sale
-361.56
-286.42%
193.95
+83.72%
105.57
+125.60%
-412.38
Purchase Of Investment
-1,209.79
-148.70%
-486.44
+50.58%
-984.34
+39.13%
-1,617.00
Sale Of Investment
848.23
+24.67%
680.39
-37.57%
1,089.91
-9.52%
1,204.61
Net Business Purchase And Sale
255.07
0.00
0.00
0.00
Purchase Of Business
-0.08
0.00
0.00
—
Gain Loss On Sale Of Business
-255.15
0.00
0.00
—
Financing Cash Flow
478.05
+6079.54%
7.74
-97.20%
276.45
+147.74%
111.59
Cash Flow From Continuing Financing Activities
478.05
+6079.54%
7.74
-97.20%
276.45
+147.74%
111.59
Net Issuance Payments Of Debt
0.00
+100.00%
-0.48
+78.46%
-2.25
+1.53%
-2.29
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-0.48
+78.46%
-2.25
+1.53%
-2.29
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
0.00
+100.00%
-0.48
+78.46%
-2.25
+1.53%
-2.29
Net Long Term Debt Issuance
0.00
+100.00%
-0.48
+78.46%
-2.25
+1.53%
-2.29
Net Common Stock Issuance
470.51
0.00
-100.00%
269.54
+148.98%
108.26
Proceeds From Stock Option Exercised
7.54
-8.33%
8.22
-10.28%
9.16
+57.79%
5.81
Net Other Financing Charges
—
—
-0.63
-235.64%
-0.19
Changes In Cash
11.51
+107.45%
-154.50
-177.60%
199.09
+160.84%
-327.22
Beginning Cash Position
290.11
-34.75%
444.61
+81.09%
245.52
-57.13%
572.74
End Cash Position
301.62
+3.97%
290.11
-34.75%
444.61
+81.09%
245.52
Free Cash Flow
-360.05
-1.08%
-356.19
-94.72%
-182.93
-592.28%
-26.42
Interest Paid Supplemental Data
0.00
-100.00%
0.03
-80.00%
0.16
-57.45%
0.38
Amortization Of Securities
-15.96
+29.90%
-22.77
+23.46%
-29.74
-216.08%
-9.41
Common Stock Issuance
470.51
0.00
-100.00%
269.54
+148.98%
108.26
Earnings Losses From Equity Investments
—
0.00
0.00
-100.00%
25.50
Issuance Of Capital Stock
470.51
0.00
-100.00%
269.54
+148.98%
108.26
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Sale Of Business
255.15
0.00
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category